Interestingly, however, in the tumors analyzed in this work there was a good positive correlation between SDC2 levels and patient survival, data that has also been described in esophageal squamous cell carcinoma, prostate cancer, and pancreatic ductal adenocarcinoma, leading to the proposal that the expression levels of this molecule are of interest for diagnosis (36–38). This evidence concerns the gene SDC2 and prostate carcinoma.